Onco hires U.S. bank as capital market adviser

Executive Summary

• Onco-Innovations Ltd. has engaged a U.S. investment bank to act as its capital market adviser.
• The engagement is specifically to pursue a potential cross-listing of the company's common shares on the Nasdaq Stock Market LLC.
• The bank will also evaluate and structure a potential concurrent equity financing, though terms have not yet been finalized.

Key Details

• Adviser Engagement: A U.S. investment bank has been retained as capital market adviser.
• Strategic Goals: The mandate includes analysis and planning for Nasdaq listing requirements, regulatory considerations, and capitalization strategies.
• Financing Structure: The company intends to evaluate a potential concurrent equity offering alongside the cross-listing.
• Status of Terms: The structure and terms of the contemplated financing have not been finalized.
• Risk Factors: The company provided no assurance that the cross-listing or concurrent financing will be completed, noting that any listing is subject to meeting applicable regulatory, governance, and exchange requirements.
• Company Context: Onco-Innovations is a Canadian-based oncology company with an exclusive worldwide license to patented technology targeting solid tumors.